Physician profile
John Michael Dinkler
NPI 1710145420
$13,055.60
in general payments reported to CMS, 2019-2025
42 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $962 · 2021: $1,866 · 2022: $1,844 · 2023: $2,194 · 2024: $2,456 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,600.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,416.21 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,084.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,075.42 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $846.15 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $815.51 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $808.93 | 2019-2025 | Farxiga, Wainua |
| Novo Nordisk INC | $771.14 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $635.26 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $516.57 | 2019-2025 | |
| Amarin Pharma, INC. | $498.14 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $476.94 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $459.80 | 2019-2025 | Onpattro, Amvuttra |
| Impulse Dynamics (USA) INC. | $318.20 | 2022-2023 | Optimizer |
| Scpharmaceuticals INC. | $285.81 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $274.29 | 2024 | Arcalyst |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $267.89 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $232.27 | 2019-2024 | Evkeeza |
| Abbott Laboratories | $212.50 | 2020-2023 | Cardiomems, Jot Dx |
| Heartflow, INC. | $173.75 | 2022-2024 | |
| Cvrx, INC. | $166.22 | 2023 | Barostim Neo System |
| Genzyme Corporation | $146.93 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $131.01 | 2019-2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $130.97 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $126.14 | 2019-2024 | Lifevest |
| Bridgebio Pharma, INC. | $125.59 | 2025 | Attruby |
| Abiomed | $122.39 | 2024-2025 | Impella |
| Bardy Diagnostics, INC. | $115.00 | 2020-2021 | |
| Boston Scientific Corporation | $114.55 | 2023-2024 | Watchman, Watchman Flx |
| Lundbeck LLC | $109.72 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.83 | 2022-2025 | |
| Medicomp INC | $76.38 | 2019-2024 | Telepatch Cardiac Monitor |
| Kiniksa Pharmaceuticals, LTD. | $68.38 | 2022-2023 | Arcalyst |
| Daiichi Sankyo INC. | $68.09 | 2019-2024 | Injectafer |
| Bard Peripheral Vascular, INC. | $49.45 | 2025 | Fluency Endovascular Stent Graft |
| Arbor Pharmaceuticals, INC. | $40.03 | 2019 | |
| Bracco Diagnostics INC. | $39.43 | 2025 | |
| Philips North America LLC | $38.43 | 2022 | |
| Medtronic, INC. | $36.87 | 2024 | Linq II |
| Biotronik INC. | $24.94 | 2021-2022 | |
| Itamar Medical INC | $17.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2021 | |
| Medtronic Vascular, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dinkler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.